[go: up one dir, main page]

DK1896006T3 - Fremstillingmetode for entacapon-holdige granuler til orale doseringsformet - Google Patents

Fremstillingmetode for entacapon-holdige granuler til orale doseringsformet

Info

Publication number
DK1896006T3
DK1896006T3 DK06755404T DK06755404T DK1896006T3 DK 1896006 T3 DK1896006 T3 DK 1896006T3 DK 06755404 T DK06755404 T DK 06755404T DK 06755404 T DK06755404 T DK 06755404T DK 1896006 T3 DK1896006 T3 DK 1896006T3
Authority
DK
Denmark
Prior art keywords
entacapone
preparation
dosage form
oral dosage
containing granules
Prior art date
Application number
DK06755404T
Other languages
English (en)
Inventor
Kari Vahervuo
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37400847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1896006(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Application granted granted Critical
Publication of DK1896006T3 publication Critical patent/DK1896006T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK06755404T 2005-06-08 2006-06-07 Fremstillingmetode for entacapon-holdige granuler til orale doseringsformet DK1896006T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68833405P 2005-06-08 2005-06-08
PCT/FI2006/000182 WO2006131591A2 (en) 2005-06-08 2006-06-07 An entacapone-containing oral dosage form

Publications (1)

Publication Number Publication Date
DK1896006T3 true DK1896006T3 (da) 2009-12-07

Family

ID=37400847

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06755404T DK1896006T3 (da) 2005-06-08 2006-06-07 Fremstillingmetode for entacapon-holdige granuler til orale doseringsformet

Country Status (19)

Country Link
US (3) US20080187590A1 (da)
EP (5) EP2316448A1 (da)
JP (2) JP5336181B2 (da)
KR (2) KR101617990B1 (da)
CN (1) CN101184483B (da)
AT (1) ATE444746T1 (da)
AU (1) AU2006256724B2 (da)
CA (1) CA2611114C (da)
CY (1) CY1109587T1 (da)
DE (1) DE602006009652D1 (da)
DK (1) DK1896006T3 (da)
EA (1) EA013161B1 (da)
ES (1) ES2311442T3 (da)
MX (1) MX2007015377A (da)
NO (1) NO345046B1 (da)
PL (1) PL1896006T3 (da)
PT (2) PT1896006E (da)
SI (1) SI1896006T1 (da)
WO (1) WO2006131591A2 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2429645A (en) * 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
WO2008081268A2 (en) * 2006-12-27 2008-07-10 Wockhardt Research Centre Pharmaceutical compositions of entacapone
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
EP2293791B1 (en) * 2008-02-06 2011-11-23 Wockhardt Limited Pharmaceutical compositions of entacapone co-micronized with sugar alcohols
PL2252284T3 (pl) 2008-02-06 2011-10-31 Wockhardt Ltd Kompozycja farmaceutyczna entakaponu, lewodopy i karbidopy o poprawionej dostępności biologicznej
BRPI0916922A2 (pt) * 2008-08-22 2015-11-24 Wockhardt Research Center composição farmacêutica de liberação prolongada de entacapona ou sais da mesma
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
CN102781424B (zh) * 2010-03-04 2016-03-30 奥赖恩公司 左旋多巴、卡比多巴和恩他卡朋用于治疗帕金森病的应用
DE102010023828A1 (de) * 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
MX2013012429A (es) * 2011-04-26 2013-12-06 Innopharmax Inc Una composicion de entacopone.
CN103845318A (zh) * 2012-12-07 2014-06-11 天津市汉康医药生物技术有限公司 恩他卡朋分散片
BR112015022390A8 (pt) * 2013-03-13 2019-11-26 Neuroderm Ltd uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson
WO2015136538A1 (en) 2014-03-13 2015-09-17 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
JP6411265B2 (ja) * 2015-03-30 2018-10-24 共和薬品工業株式会社 エンタカポン含有医薬組成物
EP3236965A1 (en) * 2015-05-08 2017-11-01 Wockhardt Limited Stable pharmaceutical compositions comprising antibacterial agent
TW201717947A (zh) * 2015-08-20 2017-06-01 漢達生技醫藥股份有限公司 包含氨氯地平和右美沙芬的藥物組合物
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
EP3500246B1 (en) * 2016-08-18 2021-08-04 Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi Antiparkinson tablet formulation with improved dissolution profile
CN106236720A (zh) * 2016-08-29 2016-12-21 海南通用康力制药有限公司 一种恩他卡朋的药物组合物及其制备方法
TWI595871B (zh) * 2016-09-22 2017-08-21 生達化學製藥股份有限公司 含有兒茶酚－ｏ－甲基轉移酶抑制劑之口服醫藥組成物及其製造方法
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US20240300930A1 (en) * 2021-02-26 2024-09-12 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide
CN113274362A (zh) * 2021-03-31 2021-08-20 海南通用康力制药有限公司 恩他卡朋片的生产方法
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
GB2238047B (en) 1989-11-03 1993-02-10 Orion Yhtymae Oy Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation
US5429825A (en) * 1992-06-26 1995-07-04 Mcneil-Ppc, Inc. Rotomelt granulation
FI101039B (fi) * 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
US5562291A (en) * 1995-09-28 1996-10-08 Daniel D. Garcia Arrow tip for shooting wooden target
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
WO1998007431A1 (en) * 1996-08-22 1998-02-26 New York University Cholinesterase inhibitors for treatment of parkinson's disease
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
NZ534234A (en) * 2002-02-01 2007-05-31 Pfizer Prod Inc Dry granulated formulations of non-dihydrate form of azithromycin
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20080076825A1 (en) 2003-12-31 2008-03-27 Thomas Bader Novel Crystalline Forms of Entacapone and Production Thereof
US20060222703A1 (en) * 2005-04-01 2006-10-05 Iprbox Oy Pharmaceutical composition and preparation method thereof
WO2007073702A2 (es) * 2005-12-29 2007-07-05 Osmotica Corp. Comprimido multicapa con combinación de triple liberación
US20090155369A1 (en) * 2007-12-13 2009-06-18 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa

Also Published As

Publication number Publication date
EP1896006A2 (en) 2008-03-12
ATE444746T1 (de) 2009-10-15
US20080187590A1 (en) 2008-08-07
ES2311442T3 (es) 2010-01-07
ES2311442T1 (es) 2009-02-16
EP2308487A1 (en) 2011-04-13
CN101184483A (zh) 2008-05-21
KR20150001843A (ko) 2015-01-06
JP2008542434A (ja) 2008-11-27
JP5336181B2 (ja) 2013-11-06
AU2006256724B2 (en) 2012-06-07
EA200702616A1 (ru) 2008-04-28
US20120289594A1 (en) 2012-11-15
CA2611114A1 (en) 2006-12-14
WO2006131591A2 (en) 2006-12-14
KR101617990B1 (ko) 2016-05-03
EP2050447B1 (en) 2017-10-11
EP1896006B1 (en) 2009-10-07
PT1896006E (pt) 2009-10-19
US20130274330A1 (en) 2013-10-17
SI1896006T1 (sl) 2010-02-26
EA013161B1 (ru) 2010-02-26
EP2050447A1 (en) 2009-04-22
JP2013173760A (ja) 2013-09-05
NO20076687L (no) 2007-12-28
PL1896006T3 (pl) 2010-03-31
EP2335696A1 (en) 2011-06-22
CN101184483B (zh) 2011-08-10
AU2006256724A1 (en) 2006-12-14
CY1109587T1 (el) 2014-08-13
KR101468738B1 (ko) 2014-12-03
PT2050447T (pt) 2018-01-17
EP2316448A1 (en) 2011-05-04
MX2007015377A (es) 2008-02-14
CA2611114C (en) 2014-09-23
KR20080012945A (ko) 2008-02-12
NO345046B1 (no) 2020-09-07
DE602006009652D1 (de) 2009-11-19
WO2006131591A3 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
DK1896006T3 (da) Fremstillingmetode for entacapon-holdige granuler til orale doseringsformet
LTPA2018010I1 (lt) Žmogaus anti-IL-23 antikūnai, kompozicijos, metodai ir panaudojimai
DK3851447T3 (da) Fremgangsmåder, forbindelser, sammensætninger og vehikler til administration af 3-amino-1-propansulfonsyre
DE602006020327D1 (de) 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
NO20070753L (no) Fremgangsmåte for fremstilling av dihydropteridinoner
FR2883179B1 (fr) Comprime enrobe
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1937633T3 (da) Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
DK1817282T3 (da) Til behandling af respiratoriske sygdomme egnede phenoxy derivater
NO20055686L (no) Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav.
EA200970126A1 (ru) Способ получения прегабалина и его энантиомера
WO2007025146A3 (en) Balsalazide formulations and manufacture and use thereof
ATE496913T1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
DK1841433T3 (da) Præparat til behandling af lidelser i centralnervesystemet
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DK1659880T3 (da) Sammensætning til dyreernæring
WO2006000547A3 (de) Verfahren zur herstellung eines phosphatadsorbens auf eisensulfat-basis
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin